The clinical outcome of adult Philadelphia (Ph)-positive acute lymphoblastic leukemia (ALL).

被引：0
|
作者：
Faderl, S
Kantajian, HM
Thomas, D
Cortes, J
Giles, F
Estrov, Z
机构：
[1] Univ Texas, MD Anderson Cancer Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Cancer Ctr, Dept Bioimmunotherapy, Houston, TX 77030 USA
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
922
引用
收藏
页码：225A / 225A
页数：1
相关论文
共 50 条
  • [21] Outcome of Philadelphia positive (Ph+) childhood acute lymphoblastic leukaemia (ALL) on the MRC ALL 97/01 trial
    Roy, A
    Bradburn, M
    Moorman, A
    Burrett, J
    Mitchell, C
    Kinsey, S
    Hann, I
    Saha, V
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 : 1 - 1
  • [22] Management of adult Ph-positive acute lymphoblastic leukemia
    Chiaretti, Sabina
    Foa, Robin
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2015, : 406 - 413
  • [23] Transplant Characteristics and Outcomes of Philadelphia (Ph)-like Acute Lymphoblastic Leukemia (ALL)
    Anagnostou, Theodora
    Maloy, Molly A.
    Patnaik, Mrinal M.
    Arcila, Maria E.
    Arteaga, Alexandra Gomez
    Cho, Christina
    Dahi, Parastoo B.
    Gyurkocza, Boglarka
    Perales, Miguel
    Ponce, Doris M.
    Shaffer, Brian C.
    Taman, Roni
    Giralt, Sergio A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S114 - S115
  • [24] The Importance of Ponatinib (Iclusig®) in the Treatment of Philadelphia-Chhromosome-positive acute lymphoblastic Leukemia (Ph plus ALL)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (12)
  • [25] PONATINIB (PON) IN PHILADELPHIA CHROMOSOME (PH)-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PRELIMINARY REPORT OF THE OPAL OBSERVATORY
    Tavitian, S.
    Raffoux, E.
    Thomas, X.
    Chevallier, P.
    Hunault, M.
    Leguay, T.
    Bilger, K.
    Lepretre, S.
    Legros, L.
    Cano, I.
    Lheritier, V.
    Virlojeux, A.
    Dombret, H.
    Huguet, F.
    HAEMATOLOGICA, 2017, 102 : 352 - 353
  • [26] Philadelphia-positive (PH+) acute lymphoblastic leukemia (ALL): developing strategies for curing this stubborn disease
    Liam, Christopher Chin Keong
    Boo, Yang Liang
    Chong, Siew Lian
    Sathar, Jameela
    Ong, Tee Chuan
    Tan, Sen Mui
    BLOOD RESEARCH, 2022, 57 (02) : 158 - +
  • [27] Acute lymphoblastic leukemia Philadelphia-positive
    Delannoy, Andre
    HEMATOLOGIE, 2006, 12 : 26 - 31
  • [28] Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
    Wassmann, B
    Pfeifer, H
    Stadler, M
    Bornhäuser, M
    Bug, G
    Scheuring, UJ
    Brück, P
    Stelljes, M
    Schwerdtfeger, R
    Basara, N
    Perz, J
    Bunjes, D
    Ledderose, G
    Mahlberg, R
    Binckebanck, A
    Gschaidmeier, H
    Hoelzer, D
    Ottmann, OG
    BLOOD, 2005, 106 (02) : 458 - 463
  • [29] Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience.
    Papayannidis, Cristina
    Iacobucci, Ilaria
    Soverini, Simona
    Colarossi, Sabrina
    Gnani, Alessandra
    Lonetti, Annalisa
    Baldazzi, Carmen
    Testoni, Nicoletta
    Amabile, Marilina
    Ottaviani, Emanuela
    Abbenante, Maria Chiara
    Curti, Antonio
    Paolini, Stefania
    Lama, Barbara
    Castagnetti, Fausto
    Poerio, Angela
    Clissa, Cristina
    Parisi, Sarah
    Polverelli, Nicola
    Guadagnuolo, Viviana
    Piccaluga, Pier Paolo
    Rosti, Gianantonio
    Baccarani, Michele
    Martinelli, Giovanni
    BLOOD, 2009, 114 (22) : 800 - 800
  • [30] Further improvement of outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL) treated with imatinib-combined chemotherapy
    Ohno, R.
    Yanada, M.
    ANNALS OF HEMATOLOGY, 2008, 87 : S73 - S75
12345